Breast cancer screening rates shifted after the 2009 US Preventive Services Task Force (USPSTF) guidelines, with disparities ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Abandoning efforts to reform payment for cell and gene therapies for Medicaid beneficiaries could allow ongoing access ...

New data showed that prior malignancy may influence survival outcomes in patients with metastatic colorectal cancer, ...

With a majority vote by the Senate Finance Committee, Robert F. Kennedy Jr's nomination for health secretary is pushed to a ...

World Cancer Day also marks the start of the ‘United by Unique’ campaign, which seeks to highlight how each person’s journey ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), ...

A new meta-analysis adds to the body of literature promoting the benefits of exercise for patients with cancer.

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.

Debra Patt, MD, PhD, MBA, MPH, emphasizes advocacy for pharmacy benefit manager (PBM) reform, physician reimbursement, and sustainable policy solutions to improve access to community cancer care.

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...